March 12, 2019 / 10:57 AM / in 11 days

Lilly's combo treatment meets main goal in lung cancer late-stage study

March 12 (Reuters) - Eli Lilly and Co said on Tuesday that its combo treatment, Cyramza, met the main goal in a late-stage study in patients with a form of lung cancer.

Lilly’s Cyramza in combination with Roche Holding’s erlotinib showed a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below